FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) is marking a major milestone in its Asia-Pacific (APAC) expansion. Serving as a strategic hub supporting customers across APAC and worldwide, the Singapore facility has contributed to Cytek’s growth over the past 12 months, significantly enhancing Cytek’s manufacturing capacity, regional service and training capabilities, a ...

Cytek Biosciences FY Conference Summary Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Cell analysis, specifically focusing on flow cytometers - **Growth Recognition**: Named one of the leading growth companies in the U.S. by Time Magazine [2][4] Key Financial Metrics - **Revenue**: $201.5 million in FY 2025, representing a 1% growth year-over-year despite a 4% decline in the overall flow cytometry market [4][11] - **Cash Position**: $261.5 million since going public, with positive cash flow generation [4][5] - **Market Share**: Cytek outperformed the market by gaining market share during a period of overall market decline [4][11] Product Launches and Innovations - **New Products**: - **Aurora Evo**: Launched in 2025, received positive feedback and is now a dominant product in sales [21][17] - **Muse Macro**: Awarded the BioTech Breakthrough Award of 2025 [2] - **Product Portfolio**: Broad range of instruments and reagents, including high-end products like Aurora Evo and CellSorter, and mid-level applications like Northern Lights and Muse Micro [12][17] Market Dynamics - **Flow Cytometry Market**: Estimated to grow from $5 billion to $9.2 billion by 2032, with a CAGR of 8.8% [11] - **Geographic Revenue Distribution**: - 47% from the U.S. - 28% from APAC - 25% from the rest of the world [7] - **Regional Growth**: APAC is expected to grow faster than the U.S., with government incentives driving investment in China [33] Customer Segments - **Revenue by Industry**: - 58% from pharma, biotech, and CROs - 42% from academic and government sectors [8] - **Customer Base**: Approximately 3,000 unique institutions and over 24,000 users on Cytek Cloud [3][14] Future Growth Drivers - **Service and Reagents**: Expected to grow at rates consistent with 2025, with a target of increasing recurring revenue from 34% to 40% over the next few years [17][24] - **Clinical Applications**: Expansion in Europe and China, with partnerships to drive clinical adoption [15][19] - **Installed Base**: Growing installed base is expected to generate consistent revenue growth [40] Challenges and Market Sentiment - **Funding Concerns**: Academic and government markets faced funding cuts, but sentiment has improved compared to the previous year [26][29] - **Pharma Spending**: While there were contractions in 2025, a return to growth is anticipated in 2026 as funding is reevaluated [28][30] Conclusion - **Strategic Positioning**: Cytek is well-positioned to capitalize on market growth through innovation, geographic expansion, and a diversified customer base. The company continues to outperform the market and is expected to maintain its growth trajectory in the coming years [10][39]

Core Insights - Cytek Biosciences reported a record fourth-quarter revenue of $62.1 million, representing an 8% year-over-year increase, attributed to stabilization in the U.S., growth in the E.U., and strong performance in APAC [3][6] - The company ended 2025 with a net loss of $44.1 million, which included a significant non-cash deferred tax valuation allowance [5][13] - Cytek initiated 2026 revenue guidance of $205–212 million, assuming improved market conditions in EMEA and the U.S., along with continued growth in service and reagents [4][16] Revenue Growth - EMEA revenue grew 21% in Q4, driven by services and instruments for academic and government customers, while U.S. revenue grew 5% with double-digit service revenue growth [1][2] - The company experienced double-digit year-over-year revenue growth in both EMEA and APAC during Q4, with mid-single-digit growth in the U.S. [2] Profitability and Margins - GAAP gross margin fell to 53% in Q4, down from 59% a year earlier, attributed to higher costs in service and product gross margins [11] - Adjusted EBITDA for 2025 declined to $5.0 million from $22.4 million in the previous year [5][14] Installed Base and Product Performance - Cytek expanded its global installed base by 208 instruments in Q4, ending 2025 with 3,664 units installed [7] - The launch of the Cytek Aurora Evo system contributed to a 21% unit growth in the Aurora category in Q4 [7] Recurring Revenue and Reagents - Recurring revenue represented 34% of total revenue for 2025, increasing 21% year-over-year [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year, driven by initiatives such as faster delivery times and a larger catalog [8] Cash Position and Share Buybacks - Cytek ended 2025 with $261.5 million in cash and equivalents, with a slight negative free cash flow of -$0.2 million in Q4 [15] - The company repurchased approximately $15.1 million of stock during 2025, representing about 3.3 million shares [15] Future Outlook - The company expects continued strong growth in service and reagents but anticipates only modest growth in instruments [17] - Management plans to invest commercially in segments where the company is currently weak, including enhancements to the reagent sales force [17]

分组1 - Cytek Biosciences reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.02, compared to earnings of $0.07 per share a year ago, resulting in an earnings surprise of -166.67% [1] - The company posted revenues of $62.14 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.23%, and showing an increase from year-ago revenues of $57.48 million [2] - Cytek Biosciences shares have declined approximately 13.5% since the beginning of the year, while the S&P 500 has gained 1.5% [3] 分组2 - The earnings outlook for Cytek Biosciences is mixed, with the current consensus EPS estimate for the coming quarter at -$0.04 on revenues of $44.44 million, and -$0.02 on revenues of $207.38 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][15] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [7][25] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross profit margin of 53% compared to 59% in the prior year [18][19] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [22][30] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025, with a 26% increase in Q4 compared to the prior year [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of products [10][17] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [17] Market Data and Key Metrics Changes - EMEA and APAC regions posted double-digit year-over-year revenue growth in Q4, with EMEA driven by strong instrument demand from academic and government customers [5][15] - U.S. revenue saw mid-single digit growth in Q4, driven by academic and government market sentiment, but was offset by declines in biotech and pharma instrument sales [6][15] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions through strategic pillars: instrument, application, bioinformatics, and clinical [8] - The focus remains on driving market penetration of instrument platforms, advancing technological leadership, and growing recurring revenue lines [35] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, with expectations for continued growth in 2026, particularly in service and reagent businesses [14][33] - The company anticipates a revenue outlook for 2026 between $205 million and $212 million, reflecting improved market conditions in EMEA and the U.S. [33] Other Important Information - The company established a new manufacturing facility in Singapore, which began generating revenue within 100 days of build-out, enhancing its operational resilience [12] - Cash and marketable securities totaled $261.5 million as of December 31, 2025, reflecting a decrease from the previous year due to stock repurchase activities [32] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with catch-up disbursements from the NIH [44] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [52] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in high-end market segments and in its reagent sales force to drive future revenue growth [54][55]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest revenue achieved in a quarter historically for the company [4][15] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable improvement in revenue growth during the second half of the year [7][25] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross profit margin of 53% compared to 59% in the prior year [18][19] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [22][23] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025 compared to the prior year, with a 26% growth in Q4 over the prior year period [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of reagents [10][17] - Service revenue grew 25% in Q4 versus the prior year quarter, supported by an expanding installed base and active usage of systems [17] Market Data and Key Metrics Changes - In the U.S., total revenue saw mid-single digit year-over-year growth in Q4, driven by academic and government market sentiment [6] - EMEA and APAC both posted double-digit year-over-year revenue growth in Q4, with EMEA driven by strong instrument demand from academic and government customers [5][15] - APAC revenue grew 15% in Q4, driven by growth in instruments, service, and reagents [18] Company Strategy and Development Direction - The company aims to reinforce its position as a market leader in next-gen cell analysis solutions through strategic pillars including instruments, applications, bioinformatics, and clinical [8] - The focus remains on driving market penetration of instrument platforms, advancing technological leadership, and growing recurring revenue lines [35] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, with expectations for continued growth in 2026, particularly in service and reagent businesses [14][33] - The company anticipates a revenue outlook for 2026 between $205 million and $212 million, reflecting improved market conditions in EMEA and the U.S. [33] Other Important Information - The company established a new manufacturing facility in Singapore, which began generating revenue in less than 100 days from build-out [12] - Cash and marketable securities totaled $261.5 million as of December 31, 2025, reflecting a decrease from the previous year due to stock repurchase activities [32] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with some catch-up disbursements from the NIH [44][46] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing multiple systems [52] Question: How is the company thinking about commercial investments in 2026? - The company is focused on high-end market segments and plans to continue investing in those areas to drive future revenue growth [54][55]

Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][14] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [6][24] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross margin of 53% compared to 59% in the prior year [17][18] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [20][22] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025 compared to the prior year, with a 26% growth in Q4 [8] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of reagents [10][16] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [16] Market Data and Key Metrics Changes - In the U.S., total revenue grew by 5% in Q4, driven by double-digit growth in service revenue, while EMEA grew 21% due to strong demand from academic and government customers [17] - APAC, including China, experienced a 15% growth in Q4, driven by increases in instruments, service, and reagents [17] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions by focusing on core strategic pillars: instrument, application, bioinformatics, and clinical [7] - The company plans to continue expanding its global footprint and enhancing its operational capabilities, including a new manufacturing facility in Singapore [11] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, particularly in academic and government spending, which contributed to the revenue growth in Q4 [42] - The company anticipates continued growth in 2026, with a revenue outlook of $205 million to $212 million, reflecting improved market conditions in EMEA and the U.S. [31][32] Other Important Information - The company reported a free cash flow of -$0.2 million in Q4, with total cash and marketable securities at $261.5 million as of December 31, 2025 [24][30] - The company repurchased approximately $15.1 million of its stock during 2025, reflecting a commitment to returning value to shareholders [30] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with some catch-up disbursements from the NIH [42][43] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [50] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in its sales teams and reagent sales force to drive future revenue growth [52][53]

Revenue and International Operations - A significant portion of the company's revenues is derived from international operations, which exposes it to foreign currency exchange risk[240]. - Revenue is generated globally, mainly in the United States, Europe, and Asia, with foreign currency risk impacting revenue and operating results due to fluctuations in exchange rates[517]. - The company has not entered into any hedging arrangements to minimize the impact of foreign currency fluctuations but intends to reassess its approach as international operations grow[518]. - Inflation and foreign currency risk did not have a material effect on the company's business, financial condition, or results of operations during the periods presented[519]. Regulatory Compliance and Legal Risks - The company plans to seek FDA approval for clinical use of its systems in the United States and other countries, which may require substantial resources and time[243]. - Regulatory compliance costs may increase significantly due to stringent FDA oversight and potential changes in regulations affecting medical devices[244]. - The company may face enforcement actions from the FDA if products labeled as RUO are deemed intended for clinical diagnostic use, which could adversely affect revenue[242]. - The company is subject to ongoing regulatory obligations that may result in significant additional expenses and penalties for non-compliance[244]. - Data privacy and security laws, including the GDPR and CCPA, impose strict requirements that could increase compliance costs and legal risks for the company[257][255]. - Non-compliance with data privacy laws could lead to substantial fines, penalties, and reputational harm[258]. - The company may face product recalls due to safety issues, which could divert resources and negatively impact financial performance[248]. - Off-label use of products may result in product liability claims, which could be costly and harm the company's reputation[250]. - The company faces challenges in transferring personal information across jurisdictions due to data localization laws and GDPR restrictions, which could impede business operations and increase compliance costs[259]. - The U.S. Department of Justice has implemented a rule that restricts data transactions with certain countries, potentially impacting vendor engagements and data sharing, with significant penalties for violations[260]. - Compliance with the Payment Card Industry Data Security Standard (PCI DSS) is mandatory, with potential penalties ranging from $5,000 to $100,000 per month for noncompliance, which could affect reputation and revenue[262]. - The company is subject to evolving data privacy and security obligations, which may require significant resources to comply and could necessitate changes to business models[264]. - Regulatory scrutiny regarding AI technologies is increasing, with potential fines under the EU AI Act reaching up to €35 million or 7% of total worldwide annual turnover for non-compliance[272]. - Privacy laws may extend consumer rights that conflict with the company's use of AI technologies, potentially leading to regulatory fines and operational changes[273]. - Sensitive information input into third-party AI technologies poses risks of leakage or unauthorized disclosure, which could harm the company's reputation and operations[274]. - The rapid evolution of AI technologies and regulatory landscapes may result in increased scrutiny and legal liabilities, adversely affecting the company's financial condition and operations[275]. - The company is exposed to substantial penalties if it fails to comply with U.S. federal and state healthcare laws, which could harm its business operations and financial condition[276]. - The Anti-Kickback Statute prohibits remuneration to induce referrals or purchases under federal healthcare programs, with violations potentially leading to false claims under the FCA[276]. - The FCA allows for treble damages and mandatory monetary penalties for each false claim, which could result in significant financial exposure for the company[279]. - Compliance with federal and state anti-fraud laws may incur substantial costs, and violations could lead to criminal, civil, and administrative penalties, including exclusion from federal healthcare programs[279]. Intellectual Property and Patent Risks - The company has 34 issued U.S. utility patents and 70 pending utility patent applications as of December 31, 2025, indicating a strong focus on intellectual property protection[288]. - The issued patents are expected to expire between 2026 and 2041, which may impact the company's competitive advantage if new patents are not secured[288]. - The company’s Shanghai subsidiary owns 12 issued utility patents and has two pending invention patent applications, while the Wuxi subsidiary holds 42 issued utility patents[288]. - Regulatory scrutiny and enforcement activity regarding manufacturer reimbursement support activities have increased, posing risks to the company's operations[277]. - The company has adopted a code of business conduct and ethics, but identifying and deterring misconduct may not always be effective, leading to potential legal and financial repercussions[283]. - The company must navigate various state laws, including the CCPA, which imposes obligations on the handling of personal information and could result in civil penalties for violations[280]. - The company faces uncertainty regarding the timely issuance of pending patent applications, which may not result in commercially viable patents[289]. - There is a risk that the company's patents may be challenged, leading to potential invalidation or reduced enforceability, which could increase competition[290]. - Defects in patent preparation or filing could compromise the validity of patents, impacting the company's ability to prevent competition[291]. - The strength and enforceability of patent rights are subject to complex legal challenges, which could materially harm the company's business[292]. - The company may lose patent protection as patents have a limited lifespan, generally 20 years for utility patents in the U.S., potentially reducing competitive advantages[294]. - Joint ownership of patents with third parties could limit the company's ability to enforce its rights and protect its intellectual property[296]. - The company may struggle to acquire necessary licenses from third-party intellectual property holders, impacting product development[297]. - Non-compliance with procedural requirements for maintaining intellectual property could lead to loss of rights, allowing competitors to enter the market[302]. - Limited foreign intellectual property rights may hinder the company's ability to protect its inventions globally, exposing it to competition[303]. - The company faces significant challenges in protecting intellectual property rights in foreign jurisdictions, which may lead to substantial costs and risks of patent invalidation[304]. - Changes in U.S. patent law, particularly the transition to a first-to-file system, could impair the company's ability to protect its products and increase uncertainties in patent prosecution[305][306]. - The America Invents Act allows third-party submissions of prior art and introduces post-grant proceedings, potentially increasing costs and uncertainties in patent enforcement[307][308]. - Recent U.S. Supreme Court rulings have created uncertainties regarding the validity and enforceability of patents, which could weaken the company's ability to obtain and enforce patents[309]. - The company may incur significant expenses from litigation related to intellectual property claims, including damages and settlement payments, as seen in the settlement with BD[311]. - The competitive landscape in the flow cytometry industry is dynamic, with ongoing litigation risks that could delay product sales and marketing efforts[310]. - The company may face claims from third parties asserting that its products infringe on their patents, which could require costly litigation and impact commercialization efforts[316][319]. - Engaging in litigation to defend against infringement claims is expensive and time-consuming, potentially diverting resources from business operations[318]. - Compulsory licensing laws in various countries may compel the company to grant licenses to third parties, diminishing the value of its patents and harming its competitive position[322]. - The company may be subject to claims regarding the wrongful use of trade secrets by employees or consultants, which could lead to litigation and loss of valuable intellectual property rights[323]. - The company relies on trade secrets and technological innovation to maintain a competitive position, which may be difficult to protect[325]. - There is a risk of breaches in confidentiality agreements that could lead to unauthorized disclosure of proprietary information, adversely affecting the company's competitive position[326]. Financial Position and Stock Performance - The market price of the company's common stock has been highly volatile, influenced by various factors including limited trading volume and market conditions[331]. - The company has broad discretion over cash usage, intending to fund manufacturing, sales, marketing, and research and development activities, which may not yield returns[335]. - Future sales of common stock could lead to dilution of ownership and a decline in market price, impacting the ability to raise capital[336]. - Concentration of stock ownership among executives and directors may limit the influence of new investors on corporate decisions[339]. - The company does not intend to pay dividends in the foreseeable future, relying on stock price appreciation for investor returns[340]. - Disclosure controls may not prevent all errors or fraud, potentially leading to misstatements that are not detected[341]. - Anti-takeover provisions in the company's charter could delay or prevent changes in control, affecting stockholder interests and market price[344]. - The company had cash and cash equivalents of $90.9 million as of December 31, 2025, primarily consisting of money market funds and bank deposits[515]. - The company does not anticipate material risk due to changes in interest rates because of the short-term nature of its cash and cash equivalents[516].

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 20 ...

Core Insights - Cytek Biosciences, Inc. will participate in the TD Cowen 46 Annual Health Care Conference in Boston, MA [1] - The management is scheduled for a hybrid presentation and fireside chat on March 4 at 8:10 a.m. Pacific Time [2] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that focuses on high-resolution, high-content, and high-sensitivity cell analysis using its patented Full Spectrum Profiling™ (FSP) technology [3] - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [3] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3] Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [4] Information Distribution - Cytek utilizes its website, LinkedIn page, and X account, in addition to SEC filings and press releases, to distribute material information and comply with disclosure obligations [5]